{"id":609528,"date":"2023-02-18T20:49:46","date_gmt":"2023-02-19T02:49:46","guid":{"rendered":"https:\/\/news.sellorbuyhomefast.com\/index.php\/2023\/02\/18\/uk-biontech-test-mrna-against-cancer\/"},"modified":"2023-02-18T20:49:46","modified_gmt":"2023-02-19T02:49:46","slug":"uk-biontech-test-mrna-against-cancer","status":"publish","type":"post","link":"https:\/\/newsycanuse.com\/index.php\/2023\/02\/18\/uk-biontech-test-mrna-against-cancer\/","title":{"rendered":"UK, BioNTech test mRNA against cancer"},"content":{"rendered":"<p>Science &#038; Nature <\/p>\n<div data-track-component=\"article body\">\n<article lang=\"en\">\n<div>\n<header>\n<ul data-test=\"article-identifier\">\n<li data-test=\"article-category\">News in Brief<\/li>\n<li><a href=\"http:\/\/www.nature.com\/#article-info\" data-track=\"click\" data-track-action=\"publication date\" data-track-label=\"link\">Published: <time datetime=\"2023-02-15\">15 February 2023<\/time><\/a><\/li>\n<\/ul>\n<ul data-test=\"authors-list\" data-component-authors-activator=\"authors-list\"><\/ul>\n<p data-container-section=\"info\">\n<p>    <a data-test=\"journal-link\" href=\"http:\/\/www.nature.com\/nbt\"><i data-test=\"journal-title\">Nature Biotechnology<\/i><\/a><\/p>\n<p>                        <b data-test=\"journal-volume\"><span>volume<\/span>\u00a041<\/b>,\u00a0<span>page <\/span>162 (<span data-test=\"article-publication-year\">2023<\/span>)<a href=\"http:\/\/www.nature.com\/#citeas\" data-track=\"click\" data-track-action=\"cite this article\" data-track-label=\"link\">Cite this article<\/a>\n                    <\/p>\n<div>\n<ul>\n<li>\n<p>1521 <span>Accesses<\/span><\/p>\n<\/li>\n<li>\n<p>4 <span>Altmetric<\/span><\/p>\n<\/li>\n<li>\n<p><a href=\"http:\/\/www.nature.com\/articles\/s41587-023-01693-z\/metrics\" data-track=\"click\" data-track-action=\"view metrics\" data-track-label=\"link\" rel=\"nofollow\">Metrics <span>details<\/span><\/a><\/p>\n<\/li>\n<\/ul><\/div>\n<\/header><\/div>\n<div>\n<div>\n<div>\n<p>The <a href=\"https:\/\/www.gov.uk\/government\/news\/new-partnership-to-boost-research-into-vaccines-for-cancer\">UK government will partner<\/a> with BioNTech to fast-track up to 10,000 patients into clinical trials of mRNA immunotherapies to treat cancer. The alliance builds on lessons learned during the COVID-19 pandemic, during which vaccine development accelerated because the country\u2019s National Health Service (NHS), academia, the regulator and the private sector worked together, according to a <a href=\"https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-announces-strategic-partnership-uk-government-provide\">BioNTech press release<\/a>.<\/p>\n<div data-test=\"illustration\" id=\"i1\">\n<div><picture><source type=\"image\/webp\" ><img decoding=\"async\" alt aria-describedby=\"i1-desc\" width=\"300\" src=\"http:\/\/media.springernature.com\/w300\/springer-static\/image\/art%3A10.1038%2Fs41587-023-01693-z\/MediaObjects\/41587_2023_1693_Figa_HTML.png\"><\/picture><\/div>\n<p><span data-test=\"illustration-credit\"><br \/>\n            Credit: Backyard Productions \/ Alamy Stock Photo<\/span><\/p>\n<\/div>\n<\/div>\n<p>The project, dubbed the Cancer Vaccine Launch Pad and run by the NHS and Genomics England, will recruit patients starting September 2023 to take advantage of the clinical trial, genomics and centralized healthcare data <a href=\"https:\/\/doi.org\/10.1038\/d41573-021-00068-w\">infrastructure<\/a> afforded by the NHS.<\/p>\n<p>The trials of yet undisclosed mRNA cancer immunotherapies in adjuvant or metastatic settings will run until 2030. Around one-third of BioNTech\u2019s wholly owned mRNA vaccine candidates are already in UK trials, all using a fixed combination of mRNA-encoded tumor-associated antigens. These include BNT111 for advanced melanoma, BNT112 for prostate cancer and BNT113 for head and neck and other cancers.<\/p>\n<p>Also as part of the agreement, the Mainz, Germany-based BioNTech will set up an R&#038;D hub in Cambridge, UK employing around 70 researchers, as well as an office in London.<\/p>\n<\/p><\/div>\n<div>\n<div id=\"rightslink-section\" data-title=\"Rights and permissions\">\n<h2 id=\"rightslink\">Rights and permissions<\/h2>\n<\/div>\n<div id=\"article-info-section\" aria-labelledby=\"article-info\" data-title=\"About this article\">\n<h2 id=\"article-info\">About this article<\/h2>\n<div id=\"article-info-content\">\n<p><a data-crossmark=\"10.1038\/s41587-023-01693-z\" target=\"_blank\" rel=\"noopener\" href=\"https:\/\/crossmark.crossref.org\/dialog\/?doi=10.1038\/s41587-023-01693-z\" data-track=\"click\" data-track-action=\"Click Crossmark\" data-track-label=\"link\" data-test=\"crossmark\"><img loading=\"lazy\" decoding=\"async\" width=\"57\" height=\"81\" alt=\"Science &amp; Nature Verify currency and authenticity via CrossMark\" src=\"data:image\/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\"><\/a><\/p>\n<div>\n<h3 id=\"citeas\">Cite this article<\/h3>\n<p> UK, BioNTech test mRNA against cancer.<br \/>\n                    <i>Nat Biotechnol<\/i> <b>41<\/b>, 162 (2023). https:\/\/doi.org\/10.1038\/s41587-023-01693-z<\/p>\n<p><a data-test=\"citation-link\" data-track=\"click\" data-track-action=\"download article citation\" data-track-label=\"link\" data-track-external rel=\"nofollow\" href=\"https:\/\/citation-needed.springer.com\/v2\/references\/10.1038\/s41587-023-01693-z?format=refman&#038;flavour=citation\">Download citation<\/a><\/p>\n<ul data-test=\"publication-history\">\n<li>\n<p>Published<span>: <\/span><span><time datetime=\"2023-02-15\">15 February 2023<\/time><\/span><\/p>\n<\/li>\n<li>\n<p>Issue Date<span>: <\/span><span><time datetime=\"2023-02\">February 2023<\/time><\/span><\/p>\n<\/li>\n<li>\n<p><abbr title=\"Digital Object Identifier\">DOI<\/abbr><span>: <\/span><span>https:\/\/doi.org\/10.1038\/s41587-023-01693-z<\/span><\/p>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/div>\n<p><a href=\"https:\/\/www.nature.com\/articles\/s41587-023-01693-z\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><br \/>\n Camellia Wrona<\/p>\n","protected":false},"excerpt":{"rendered":"<p>News in Brief Published: 15 February 2023 Nature Biotechnology volume\u00a041,\u00a0page 162 (2023)Cite this article 1521 Accesses 4 Altmetric Metrics details The UK government will partner with BioNTech to fast-track up to 10,000 patients into clinical trials of mRNA immunotherapies to treat cancer. The alliance builds on lessons learned during the COVID-19 pandemic, during which vaccine<\/p>\n","protected":false},"author":1,"featured_media":609529,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33889,1070,536],"tags":[],"class_list":{"0":"post-609528","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-biontech","8":"category-cancer","9":"category-science-nature"},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/609528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/comments?post=609528"}],"version-history":[{"count":0,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/posts\/609528\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media\/609529"}],"wp:attachment":[{"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/media?parent=609528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/categories?post=609528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsycanuse.com\/index.php\/wp-json\/wp\/v2\/tags?post=609528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}